From Petra report today:
The final 2nd line head and neck data in the ASCO abstract for overall treatment group was largely consistent with interim data reported in 2021, showing efti when added to Merck’s Keytruda is doubling the number of patients who could benefit from treatment, however the median overall survival came down (now at par with Keytruda rather than superior). While there is still a compelling case just for expanding Keytruda’s reach, we believe the data in the more relevant PD-L1 positive group (to be released on 5th June at ASCO) is likely to continue to show improved survival outcomes as well making the case stronger. PD-L1 positives are the focus of the larger TACTI-003 trial in 1st line head & neck. In our view, the negative market reaction is therefore excessive and premature. No change to our view on IMM. We re-iterate our Buy and $1.28/sh TP.
- Forums
- ASX - By Stock
- IMM
- Ann: Publication of Abstracts for ASCO 2023 Annual Meeting
Ann: Publication of Abstracts for ASCO 2023 Annual Meeting, page-29
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
41.0¢ |
Change
0.005(1.23%) |
Mkt cap ! $588.3M |
Open | High | Low | Value | Volume |
41.0¢ | 41.5¢ | 40.5¢ | $302.2K | 736.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 114995 | 40.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
41.0¢ | 94069 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 106303 | 0.405 |
15 | 107449 | 0.400 |
12 | 163337 | 0.395 |
8 | 75700 | 0.390 |
6 | 54364 | 0.385 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 93456 | 14 |
0.415 | 185837 | 13 |
0.420 | 508600 | 12 |
0.425 | 77529 | 9 |
0.430 | 35281 | 8 |
Last trade - 12.08pm 13/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |